Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accounts Payables (2022 - 2025)

Gossamer Bio's Accounts Payables history spans 4 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 156.96% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, up 156.96%, while the annual FY2025 figure was $6.0 million, 156.96% up from the prior year.
  • Accounts Payables reached $6.0 million in Q4 2025 per GOSS's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.0 million in Q4 2025 to a low of $363000.0 in Q3 2022.
  • Average Accounts Payables over 4 years is $2.5 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: soared 361.32% in 2023, then plummeted 63.49% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $1.5 million in 2022, then skyrocketed by 278.75% to $5.5 million in 2023, then tumbled by 58.03% to $2.3 million in 2024, then soared by 156.96% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Accounts Payables are $6.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.9 million (Q2 2025).